Physician profile
Mallory Cless
NPI 1649847203
$3,278.05
in general payments reported to CMS, 2019-2025
42 companies · $2,618 in 2025
The $2,618 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $660 · 2025: $2,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,278.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390.57 | 2024-2025 | |
| Pfizer INC. | $332.72 | 2024-2025 | |
| Glaxosmithkline, LLC. | $251.16 | 2024-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Otsuka America Pharmaceutical, INC. | $173.39 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.22 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $148.27 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $119.13 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $114.04 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $113.61 | 2024-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $109.10 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.94 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $104.42 | 2024-2025 | Breztri, Fasenra, Airsupra |
| Amgen INC. | $89.26 | 2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.91 | 2024-2025 | Jardiance |
| Lundbeck LLC | $79.65 | 2025 | Rexulti |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $78.86 | 2025 | Zurzuvae |
| Bausch Health US, LLC | $77.74 | 2024-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $60.51 | 2024-2025 | Fanapt |
| Viiv Healthcare Company | $57.66 | 2025 | Apretude |
| Mayne Pharma Commercial LLC | $53.58 | 2025 | |
| Aimmune Therapeutics, INC. | $50.21 | 2025 | Zenpep |
| Indivior INC. | $43.55 | 2024-2025 | Sublocade |
| Verity Pharmaceuticals INC. | $38.66 | 2025 | Tlando |
| Lilly USA, LLC | $33.52 | 2025 | Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $30.98 | 2025 | |
| Agios Pharmaceuticals, INC. | $28.76 | 2024 | |
| Sanofi-Aventis U.S. LLC | $28.55 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $24.98 | 2025 | Zoryve |
| Biomarin Pharmaceutical INC. | $24.70 | 2025 | Voxzogo 1.2mg |
| Abbott Laboratories | $24.48 | 2024 | Freestyle Libre 3 |
| Organon LLC | $22.69 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $21.54 | 2025 | |
| Coopersurgical, INC. | $21.30 | 2025 | Paragard T 380a |
| Phathom Pharmaceuticals, INC. | $21.14 | 2024 | Voquezna |
| Almatica Pharma LLC | $20.01 | 2024 | Loreev Xr, Teriparatide |
| Edwards Lifesciences Corporation | $19.68 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Dynavax Technologies Corporation | $19.61 | 2025 | Heplisav-B |
| Fidia Pharma USA INC. | $18.25 | 2025 | Triluron |
| Takeda Pharmaceuticals U.S.A., INC. | $17.36 | 2025 | Trintellix |
| Minerva Surgical, INC | $16.36 | 2025 | |
| Inspire Medical Systems, INC. | $16.31 | 2025 | Inspire |
| Azurity Pharmaceuticals, INC. | $15.67 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Cless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.